<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"><channel><title>RSS Feed on Applied Radiology</title><link>http://www.appliedradiology.com</link><description> RSS Feed on Applied Radiology</description><item><title>Uterine artery embolization for fibroids: Procedure, Results and Complications`</title><link>http://www.appliedradiology.com//Issues/2001/07/Supplements/Uterine-artery-embolization-for-fibroids--Procedure,-Results-and-Complications`.aspx</link><description>Deep venous thrombosis (DVT) is a major medical problem with significant morbidity and mortality from its associated complications, such as pulmonary embolism, post-thrombotic syndrome, and phlegmasia cerulea dolens. Catheter-directed thrombolysis is a promising and relatively new technique to treat acute DVT and to relieve its symptoms rapidly. The recent unavailability of urokinase has resulted in an increased demand for other thrombolytic agents. Alteplase has demonstrated similar success and complication rates, but with the added benefits of a shorter infusion time and lower cost. Reteplase is a newer thrombolytic agent, and preliminary results have been encouraging, especially when reteplase infusion is combined with the administration of glycoprotein IIb/IIIa inhibitors. Mechanical thrombectomy, particularly when used in conjunction with catheter-directed thrombolysis, is an encouraging technique to further improve the interventionalist's ability to treat DVT and is undergoing continued investigation. This article will review recent advances in the area of catheter-directed thrombolysis for DVT, including several abstracts presented at the recent Society of Cardiovascular and Interventional Radiology 2001 Annual Meeting. 
fibroids may be the most common tumor found anywhere in the body. Many uterine fibroids
are symptomatic, leading most commonly to abnormal uterine bleeding, a sensation of pelvic pressure, and the effects of compression of adjacent organs by an enlarged uterus. Selective UAE devascularizes uterine fibroids, leading to shrinkage of the fibroids and, more importantly, significant amelioration of symptoms.
Early results of this minimally invasive therapy have been impressive, with resolution or significant reduction of symptoms achieved generally in the
range of 90% to 95% out as long as 2 years. The low rate of serious complications has also been impressive to this point. The purpose of this paper is to provide interven-tional radiologists with a review of the body of literature regarding this exciting new application
of embolotherapy.</description><author></author><pubDate>Wednesday, 05 Sep 2001 20:29:23 GMT</pubDate></item></channel></rss>